TickerGuard
Buy Day today: Poor (44) Weak market breadth · major macro event coming up
RGNX

Regenxbio Inc

Healthcare · Biotechnology

7.50$ -8.0% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Cash Flow

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Cash Flow RGNX
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
-202.9% -194.8%
+0.0% +580.0% +393.8% +48.3% +79.6% +17.5% +13.8% +35.0% +34.2% -6.4% -3.7%
+815.7% +140.7% +50.8% +56.9% +61.4% +19.0% +21.5% +5.1% -1.3% -4.5% -10.1%
+559.1% +165.2% +34.3% +43.7% +26.9% +91.9% +1.7% +11.4%
-373.9% -82.8% -966.7% +182.8% -65.2% -177.9% +112.9%
+0.0% +1,461.1% -12.1% +85.4% -11.7% +129.3% +213.3% -63.5% -67.6% -75.5% -0.9%
+0.0% -125.0% +5,732.1% +31.2% -431.3% -97.1% -45.8% -115.3%
+23,930,900.0% -99.9% +210.6% +52.3% +55.1% +36.9% -100.1% +14,100.0% +47.5% -12.0%
+9,867.1% -100.0% +70,990.8% +141.7% -95.9% +2,290.3% -2.5% -114.8% +21.2% +26.0%
+2,649,650.0% -155.2% +36.3% -119.4% -97.2% -3,417.6% -200.2%
-230.7% -276.8%

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?